ResMed: Bi-level therapy can save adherence
By HME News Staff
Updated Tue June 5, 2018
BALTIMORE - A ResMed-sponsored study shows that shifting patients who are struggling with adherence to a PAP device to a more advanced bi-level device in the first 90 days of treatment is an effective tool in more than half of cases. In the study, ResMed compared 1,496 non-compliant patients who switched to bi-level therapy and found that compliance was achieved by 58.5% of patients who switched before day 60, 54.2% of patients who switched between days 60-90, and 56.8% of patients overall. “Finding the right mode of therapy made all the difference to those patients who are struggling with initial adherence to therapy,” said ResMed Chief Medical Officer Carlos M. Nunez, M.D. “This strongly suggests that bilevel devices provide a powerful alternative therapy that physicians and HMEs can utilize to help improve non-compliant patients' treatment experience and outcomes.” The study was presented this week at SLEEP, an annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. A bi-level device delivers two distinct pressures, one for inhalation and one for exhalation, and can be prescribed for patients who are pressure intolerant or have continued evidence of apnea at higher pressures.
Comments